Cancer cell models as a therapeutic biomarker discovery platform


Session type:

Mathew Garnett1
1Wellcome Trust Sanger Institute, Cambridge, UK


Alterations in cancer genomes strongly influence clinical responses to anti-cancer therapies. Indeed, there are now several examples where genomic changes are used as molecular biomarkers to stratify patients most likely to benefit from a treatment (e.g. BRAF in melanoma). Despite these successes, the majority of cancer drugs have not been linked to specific molecular features that could be used to direct their clinical use to maximise patient benefit.

We are performing large-scale pharmacogenomic profiling in various in vitro models of human cancer, including cancer cell lines, cancer organoids, and ex vivo PDX cultures, as a biomarker discovery platform by systematically linking drug sensitivity data with extensive genomic information. I will present results from our most current analysis of drug screening including follow-up validation studies, as well as highlight new approaches we have developed to harness clinical sequencing data to guide our analyses.